HAIKOU,
China, Dec. 5, 2022 /PRNewswire/ -- China
Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma",
the "Company" or "We"), an NYSE American-listed corporation with a
fully-integrated specialty pharmaceuticals subsidiary based in
China, today announced the
Acquisition of Dry Eye Disease Therapeutic Device Project.
- This device has a patent
- Epidemiological research shows that the incidence rate of DED
is about 25% to 30%, and the incidence rate of people over
65-year-old is 75% in China
- According to the Research Report on the Market Status of the
Global Dry Eye Disease Drug Industry in 2022(1), the
market size of DED drugs in China
in 2021 was approximately RMB3.85
billion (approximately US$0.55
billion), resulting a 12.4% year-on-year growth
- In the field of DED and visual fatigue, this product will fill
in the market gap of medical therapeutic apparatus
- We have established sales channels in more than 30 provincial
and municipal hospitals, as well as OTC markets in China for more than 20 years; which will
strongly support the launch and promotion of this device
Dry eye disease (DED) refers to the general term of a variety of
diseases related to abnormal tear quality, quantity, or dynamics,
accompanied by eye discomfort (dry eyes, tingling, burning, gritty
feeling, etc.) and/or ocular surface tissue lesions. Which may be
caused by any reason (including aging, wearing contact lenses,
certain drugs, eye diseases, other diseases, or environmental
factors).
Ms. Li Zhilin, CEO of China
Pharma said: "Due to the increasingly developed technology, the
time and frequency of using the electronic products have
significantly increased in recent years. In addition, with the
aging of the population, DED has become the largest ophthalmic
disease in China, and the
diagnosis and treatment rate is expected to maintain an upward
trend for a long time. What we acquired is an ophthalmic oxygen
enriched atomization therapeutic device with a patent technology.
This device is to fill in the vacuum of the current market demand
in devices to treat DED, visual fatigue and other problems, as well
as recovery after eye surgery. We plan to launch it to the market
next year. We are confident that the launch of this product will
bring excellent treatment experience to every DED patient, which
will also boost the Company's sales. "
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. (NYSE American: CPHI) is a specialty
pharmaceutical company that develops, manufactures, and markets a
diversified portfolio of products, focusing on conditions with high
incidence and high mortality rates in China, including cardiovascular, CNS,
infectious, and digestive diseases. The Company's cost-effective
business model is driven by market demand and supported by new
GMP-certified product lines covering the major dosage forms. In
addition, the Company has a broad and expanding nationwide
distribution network across all major cities and provinces in
China. The Company's wholly-owned
subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd.,
is located in Haikou City,
Hainan Province. For more
information about China Pharma Holdings, Inc., please visit
www.chinapharmaholdings.com. The Company routinely posts important
information on its website.
Safe Harbor Statement
Certain statements in this press release constitute
forward-looking statements for purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of
1995. Any statements set forth above that are not historical facts
are forward-looking statements that involve risks and uncertainties
that could cause actual results to differ materially from those in
the forward-looking statements. Such risks and uncertainties may
include, but are not limited to: the achievability of financial
guidance; success of new product development; unanticipated changes
in product demand; increased competition; downturns in the Chinese
economy; uncompetitive levels of research and development; and
other information detailed from time to time in the Company's
filings and future filings with the United States Securities and
Exchange Commission. The forward-looking statements made herein
speak only as of the date of this press release and the Company
undertakes no duty to update any forward-looking statement to
conform the statement to actual results or changes in the Company's
expectations, except as required by applicable law or
regulation.
(1) Source from Newsjie
View original
content:https://www.prnewswire.com/news-releases/china-pharma-holdings-inc-announced-the-acquisition-of-dry-eye-disease-therapeutic-device-project-301694458.html
SOURCE China Pharma Holdings, Inc.